Stanford University School of Medicine
Stanford, California, 94305, United States
NCT Number: NCT00186381
Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.
Looking for future studies?
Notify Me16 year–69 year
All sexes
Interventional
Phase 2
Stanford, California, 94305, United States
To use high dose chemotherapy with autologous stem cell rescue to try to increase the chance of long term control and cure of the disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- must be in remission
Stanford University
Other
Autologous Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02158858
Blood Coagulation Disorders, Blood Platelet Disorders
Phoenix, Arizona, United States
View Trial DetailsNCT02140242
Hematologic Diseases, Hemic and Lymphatic Diseases
Brno, Czechia
View Trial DetailsNCT01723657
Hematologic Diseases, Hemic and Lymphatic Diseases
Badalona, Barcelona, Spain
View Trial DetailsNCT00251368
Acute Lymphocytic Leukemia, Hematologic Diseases
Boston, Massachusetts, United States
View Trial Details